SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy

IRVINE, Calif.--(BUSINESS WIRE)--Jan 5, 2026--

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/

Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and most sophisticated platforms across a wide range of medical disciplines, continuously integrating this knowledge into a coherent platform strategy. With more than 25 years of history, the Company has developed a scalable operating model, deep clinical expertise, and a strong track record of disciplined growth—foundations that position SBC Medical to execute successfully on its next phase of international expansion.

This investment marks the beginning of SBC Medical’s full-scale strategic expansion in the U.S. market through a committed partnership with OrangeTwist, and both companies will pursue joint operations that leverage cross-border synergies between the U.S. and Asia to support long-term growth opportunities.

Founded in 2015, OrangeTwist specializes in non-invasive aesthetic treatments and currently operates 24 locations across six U.S. states. With strong medical oversight and data-driven clinical operations, the company offers a comprehensive portfolio of injectable, energy-based, and regenerative treatments. Its advanced management system integrating procurement, clinical workflows, and real-time KPI tracking provides operational consistency and supports scalable growth.

Comment from Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings
“OrangeTwist has solidified its leadership in the U.S. market by consistently delivering exceptional quality and outstanding client experiences in non-invasive aesthetic medicine. We look forward to combining their strengths with our expertise and global network to accelerate growth across Asia and beyond.”

Comment from Clint Carnell, Co-founder of OrangeTwist
“SBC Medical has built one of the most respected and sophisticated aesthetic brands internationally. Their entry into the U.S. through a partnership with OrangeTwist provides a uniquely strong operational foundation and accelerates their ability to scale in one of the largest and fastest-growing aesthetic markets in the world.”

SBC Medical Global Growth Strategy
SBC Medical’s investment in OrangeTwist is the first step in a structured, multi-year roadmap to establish a leading position in the U.S. medical aesthetics and wellness market. The partnership enables both companies to leverage cross-border synergies across clinical protocols, technology adoption, operational efficiency, and commercial strategy.

This partnership signifies the start of SBC Medical’s Phase 1 market entry initiative and lays the groundwork for future phases of scale and market leadership. By integrating a sustainable model focused on personal well-being and high-quality medical outcomes, SBC Medical aims to deliver differentiated value to customers in the U.S. and Asia, while building diversified and resilient revenue streams across geographies.

● Global Expansion Strategy Designed for Sustainable Earnings Growth
SBC Medical views international expansion—particularly in the United States and Southeast Asia—as a central pillar of its long-term value creation strategy. The Company’s global expansion thesis is guided by three core principles

1. Partnering with high-performing regional operators with demonstrated execution capability, strong brand presence, and scalable business models;
2. Deploying SBC Medical’s differentiated operating expertise, including leadership in advanced aesthetic treatments, operational excellence, and clinical safety, to drive performance uplift across partner networks; and
3. Securing first-mover advantages through access to emerging medical technologies, proprietary treatment platforms, and information-sharing mechanisms that support future innovation and margin expansion.

The Company is focused on high-growth categories within health and wellness—including regenerative medicine, aesthetic medicine, and wellness solutions—while also exploring next-generation opportunities in human optimization, longevity science, and Medicine 4.0. SBC Medical continues to evaluate strategic medical technology platforms such as AI-enabled diagnostics, telemedicine capabilities, and patient-experience technologies that align with its long-term growth priorities.

● Three-Phase Global Expansion Roadmap
The OrangeTwist partnership forms part of SBC Medical’s structured global expansion roadmap:

Phase 1: Entry (2025–2026)
Deepen market understanding, build strategic partnerships, and deploy minority investments that create optionality for future expansion.

Phase 2: Scale (2027–2028)
Leverage accumulated market intelligence and SBC Medical’s proven operating model to pursue selective acquisitions and joint ventures capable of accelerating growth and strengthening competitive positioning.

Phase 3: Leadership (2029 onward)
Establish SBC Medical as a leading operator in the United States and other priority international markets, supported by diversified revenue streams, scalable clinical platforms, and technology-driven operating leverage.

SBC Medical believes this disciplined, phased approach—combined with the stability and profitability of its Japan business—positions the Company to deliver sustainable long-term growth, improved earnings quality, and increasing global brand value.

About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations as well as medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/
For more insights and updates from SBC Holdings, follow us on LinkedIn 　

About OrangeTwist
OrangeTwist is a fast-growing national provider of medically supervised aesthetic and wellness treatments with 24 locations in CA, TX, WA, NV, CO, and NJ. OrangeTwist was co-founded by world-renowned medical director Dr. Grant Stevens, M.D. F.A.C.S. and Clint Carnell, an experienced healthcare services/medical technology executive and former CEO of the HydraFacial Company. The company delivers a curated portfolio of injectable, energy-based, and regenerative treatments through a hospitality-driven experience supported by best-in-class clinicians and strong medical oversight.
For more information, visit www.orangetwist.com.

About Hildred
Hildred is a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies. The firm specializes in partnering with management teams to help them scale their platforms, generate earnings growth, promote strategic and operational improvements, generate business development, and drive multiple expansion. For more information, visit www.hildred.com and follow the firm on LinkedIn.

About Athyrium
Athyrium is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium advises funds with over $4.6 billion in committed capital. The Athyrium team has substantial investment experience across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, healthcare focused services, and healthcare information technology. For more information, please visit www.athyrium.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s strategic investment and alliance with OrangeTwist, product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

OrangeTwist

WASHINGTON (AP) — President Donald Trump’s White House ballroom won final approval from a key agency on Thursday, despite a federal judge recently ordering a halt to construction unless Congress allows what would be the biggest structural change to the American landmark in more than 70 years.

The 12-member National Capital Planning Commission, the agency tasked with approving construction on federal property in the Washington region, went ahead with the vote because U.S. District Judge Richard Leon’s ruling — which came two days earlier — affects construction activities but not the planning process, said the commission's Trump-appointed chair, Will Scharf.

A vote of 8-1, with two commissioners voting present and one absent, allowed the plan to move forward.

Despite the agency’s approval, however, the judge’s ruling and a legal fight over the ballroom could stall progress on a legacy project that Trump is racing to see completed before the end of his term in early 2029. It’s among a series of changes the Republican president is planning for the nation’s capital to leave his lasting imprint while he’s still in office.

Before the vote, Scharf, a top White House aide, noted that Leon's order has been stayed for two weeks as the administration seeks an appeal. He said, as he understood the decision, it “really does not impact our action here today.”

Reading from notes, Scharf also delivered an impassioned defense of the project that reviewed the full history of the White House — including changes and additions that were criticized at the time they were made but have become beloved with the passage of time. He spoke about the addition of the north and south porticos and the balcony added by President Harry Truman.

Scharf suggested that Trump’s proposed ballroom will similarly come to be viewed as a wise addition — despite drawing contemporary opposition from some members of the public and government officials.

“I believe that, in time, this ballroom will be considered every bit of a national treasure as the other key components of the White House,” Scharf said.

Scharf also said the proposed ballroom has been viewed negatively because of opposition to Trump, instead of the merits, saying, “I feel that we’ve been unfairly slighted in the press and otherwise for the way we’ve gone about reviewing this particular project.”

The vote by the commission, which includes three members Trump gets to appoint, had initially been scheduled for March but was postponed to Thursday because so many people signed up to comment at the commission’s meeting last month. The comments were overwhelmingly opposed to the ballroom.

The lone “no” vote was cast by Phil Mendelson, a Democrat who chairs the Council of the District of Columbia. Linda Argo and Arrington Dixon, the two commissioners appointed by Mayor Muriel Bowser, a Democrat, voted present.

Mendelson criticized the design of the ballroom addition and how fast it was approved.

“It’s just too large,” he said.

Criticism also came from Public Citizen, a nonprofit consumer advocacy organization. One of its attorneys, Jon Golinger, said the commission had discounted opposition from city officials and thousands of people who commented against the project, and ignored the judge's ruling. Several commissioners, including Scharf, had said they took the public feedback seriously.

“This approval is illegitimate and this vote is a joke," Golinger said.

White House spokesperson Davis Ingle, commended the “decision to approve President Trump’s historic vision to build a much need ballroom at the White House.”

“We look forward to seeing the completion of this project on time and under budget," Ingle said in a statement.

Before voting, the commission considered some design changes to the 90,000-square-foot (8,400-square-meter) ballroom addition that the president announced aboard Air Force One on Sunday, as he flew back to Washington from a weekend at his Florida home.

He removed a large staircase on the south side of the building and added an uncovered porch to the west side. Architects and other critics of the project had panned the staircase as too large and basically useless since there was no way to enter the ballroom at the top.

A White House official said the president had considered comments from the National Capital Planning Commission and another oversight entity, the U.S. Commission of Fine Arts, which approved the project earlier this year, as well as members of the public.

The official, who was not authorized to publicly discuss the ballroom design and spoke on the condition of anonymity, said that additional “refinements” had been made to the building’s exterior.

The ballroom, now estimated to cost $400 million, has expanded in scope and price tag since Trump first announced the project last summer, citing a need for space other than a tent on the lawn to host important guests. Trump demolished the East Wing in October with little warning, and site preparation and underground work have been underway since then.

Two other Trump-appointed commissioners, Stuart Levenbach and James Blair, voted for the project.

Levenbach, who serves as vice chairman and is the federal government’s chief statistician, said the White House is currently “not suited” to accommodate large numbers of guests and that the addition will improve the “utility” of the compound.

He said tunnels and other structures underground at the White House made it impossible to place many features of the ballroom there, too, as some have suggested might be possible. Levenbach said the addition is a “multipurpose facility,” noting that, in addition to a ballroom, it will also have offices for the first lady, kitchen space and a theater.

“This is not an expansion for its own sake,” Levenbach said.

Blair, a deputy to White House chief of staff Susie Wiles, said visitors and guests of the president deserve a “better experience."

Scharf and Blair also said Trump will get “very limited use” of the ballroom before his term ends.

Trump went ahead with the project before seeking input from the National Capital Planning Commission and the Commission of Fine Arts, which he reconstituted with allies and supporters.

The National Trust for Historic Preservation, a private nonprofit organization, sued after Trump demolished the East Wing last fall to build the ballroom addition — a space nearly twice as big as the mansion itself.

Trump says it will be paid for with donations from wealthy people and corporations, including him, though public dollars are paying for underground bunkers and security upgrades.

The trust sought a temporary halt to construction until Trump presented the project to both commissions and Congress for approval. Leon agreed but said that his order would take effect in two weeks and that construction related to security would be allowed.

President Donald Trump answers questions from reporters after signing an executive order in the Oval Office of the White House Tuesday, March 31, 2026, in Washington. (AP Photo/Alex Brandon)

Work continues on the construction of the ballroom at the White House in Washington, Wednesday, April 1, 2026. (AP Photo/Allison Robbert)

President Donald Trump holds a rendering of the proposed new East Wing of the White House as he speaks to reporters aboard Air Force One en route from West Palm Beach, Fla., to Joint Base Andrews, Md., Sunday, March 29, 2026. (AP Photo/Mark Schiefelbein)

Work continues on the construction of the ballroom at the White House in Washington, Wednesday, April 1, 2026. (AP Photo/Allison Robbert)

President Donald Trump holds a rendering of the proposed new East Wing of the White House as he speaks to reporters aboard Air Force One en route from West Palm Beach, Fla., to Joint Base Andrews, Md., Sunday, March 29, 2026. (AP Photo/Mark Schiefelbein)